LANCET ONCOL 2019 10.1016/S1470-2045(19)30504-2
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study
Ahn1, MJ; Han, JY; Lee, KH; Kim, SW; Kim, DW; Lee, YG; Cho, EK; Kim, JH; Lee, GW; Lee, JS; Min, YJ; Kim, JS; Lee, SS; Kim, HR; Hong, MH; Ahn, JS; Sun, JM; Kim, HT; Lee, DH; Kim, S; Cho, BC

LANCET ONCOL 2019 10.1016/S1470-2045(19)30626-6
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Kato1, K; Cho, BC; Takahashi, M; Okada, M; Lin, CY; Chin, K; Kadowaki, S; Ahn, MJ; Hamamoto, Y; Doki, Y; Yen, CC; Kubota, Y; Kim, SB; Hsu, CH; Holtved, E; Xynos, I; Kodani, M; Kitagawa, Y

CANCER 2019 10.1002/cncr.32503
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer
Papadimitrakopoulou1, VA; Han, JY; Ahn, MJ; Ramalingam, SS; Delmonte, A; Hsia, TC; Laskin, J; Kim, SW; He, Y; Tsai, CM; Hida, T; Maemondo, M; Kato, T; Jenkins, S; Patel, S; Huang, XN; Laus, G; Markovets, A; Thress, KS; Wu, YL; Mok, T

J THORAC ONCOL 2019 10.1016/j.jtho.2019.06.010
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC
Antonia1, SJ; Balmanoukian, A; Brahmer, J; Ou, SHI; Hellmann, MD; Kim, SW; Ahn, MJ; Kim, DW; Gutierrez, M; Liu, SV; Schoffski, P; Jager, D; Jamal, R; Jerusalem, G; Lutzky, J; Nemunaitis, J; Calabro, L; Weiss, J; Gadgeel, S; Bhosle, J; Ascierto, PA; Rebelatto, MC; Narwal, R; Liang, MN; Xiao, F; Antal, J; Abdullah, S; Angra, N; Gupta, AK; Khleif, SN; Segal, NH

J CLIN ONCOL 2019 10.1200/JCO.19.00934
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Garon1, EB; Hellmann, MD; Rizvi, NA; Carcereny, E; Leighl, NB; Ahn, MJ; Eder, JP; Balmanoukian, AS; Aggarwal, C; Horn, L; Patnaik, A; Gubens, M; Ramalingam, SS; Felip, E; Goldman, JW; Scalzo, C; Jensen, E; Kush, DA; Hui, R

STROKE 2019 10.1161/STROKEAHA.119.026373
Circulating DNAs, a Marker of Neutrophil Extracellular Traposis and Cancer-Related Stroke: The OASIS-Cancer Study
Bang1, OY; Chung, JW; Cho, YH; Oh, MJ; Seo, WK; Kim, GM; Ahn, MJ

EUR J CANCER 2019 10.1016/j.ejca.2019.08.001
Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing
Kim1, HS; Cha, H; Kim, JH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2017.234
Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Kim1, MJ; Kim, SM; Jung, HA; Hong, JY; Chang, WJ; Choi, MK; Kim, HS; Sun, JM; Park, K; Ahn, MJ

NAT COMMUN 2019 10.1038/s41467-019-12159-9
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
Jung1, H; Kim, HS; Kim, JY; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Esteller, M; Lee, SH; Choi, JK

J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.014
DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC
Park1, S; Lee, H; Lee, B; Lee, SH; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Park, K

J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.033
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor
Kim1, Y; Kim, CH; Lee, HY; Lee, SH; Kim, HS; Lee, S; Cha, H; Hong, S; Kim, K; Seo, SW; Sun, JM; Ahn, MJ; Ahn, JS; Park, K

LUNG CANCER 2019 10.1016/j.lungcan.2019.05.024
Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma
Park1, S; Shim, JH; Lee, B; Cho, I; Park, WY; Kim, Y; Lee, SH; Choi, YL; Han, J; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

J CLIN ONCOL 2019 10.1200/JCO.2017.77.3184
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial
Cho1, J; Kim, HS; Ku, BM; Choi, YL; Cristescu, R; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

SCI REP-UK 2019 10.1038/s41598-019-48674-4
Predictive and Prognostic Value of F-18-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer
Moon1, SH; Sun, JM; Ahn, JS; Park, K; Kim, BT; Lee, KH; Ahn, MJ; Choi, JY

J THORAC ONCOL 2019 10.1016/j.jtho.2019.03.022
Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018
Remon1, J; Ahn, MJ; Girard, N; Johnson, M; Kim, DW; Lopes, G; Pillai, RN; Solomon, B; Villacampa, G; Zhou, Q

PATHOL RES PRACT 2019 10.1016/j.prp.2019.152441
Histopathologic characteristics of advanced-stage ROS1-rearranged non-small-cell lung cancers
Park1, E; Choi, YL; Ahn, MJ; Han, J

CLIN CANCER RES 2019 10.1158/1078-0432.CCR-18-2740
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Jung1, KH; LoRusso, P; Burris, H; Gordon, M; Bang, YJ; Hellmann, MD; Cervantes, A; de Olza, MO; Marabelle, A; Hodi, S; Ahn, MJ; Emens, LA; Barlesi, F; Hamid, O; Calvo, E; McDermott, D; Soliman, H; Rhee, I; Lin, R; Pourmohamad, T; Suchomel, J; Tsuhako, A; Morrissey, K; Mahrus, S; Morley, R; Pirzkall, A; Davis, SL

SCI REP-UK 2019 10.1038/s41598-019-45117-y
Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer
Bak1, SH; Park, H; Sohn, I; Lee, SH; Ahn, MJ; Lee, HY

CLIN LUNG CANCER 2019 10.1016/j.cllc.2018.12.021
Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients
Da Nam1, B; Kim, TJ; Park, K; Ahn, MJ; Choi, YL; Chung, MJ; Kim, TS; Lee, KS

J CANCER RES CLIN 2019 10.1007/s00432-019-02889-0
Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma
Cho1, JH; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM